Skip to content

MEDICUS PHARMA LTD.: 10-Q filed 2025-08-11

What MEDICUS PHARMA LTD. reported in its quarterly report filed 2025-08-11 (fiscal Q2 2025): 30 published measures, 91 facts as tagged in accession 0001062993-25-014058.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-11
Fiscal period
fiscal Q2 2025
Accession
0001062993-25-014058 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MEDICUS PHARMA LTD. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-3011,934,628USD
At 2024-12-315,646,878USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-308,685,918USD
At 2024-12-312,512,174USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-06-309,669,546USD
At 2024-12-314,164,323USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-11,278,492USD181
2024-01-01 to 2024-06-30-5,340,217USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-9,409,825USD181
2024-01-01 to 2024-06-30-3,953,639USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-06-3014,915,048USD181
2024-01-01 to 2024-06-3010,642,500USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-40,182,395USD
At 2024-12-31-28,903,903USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-04-01 to 2025-06-3014,284,261shares91
2025-01-01 to 2025-06-3013,853,305shares181
2024-04-01 to 2024-06-308,167,993shares91
2024-01-01 to 2024-06-308,122,333shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-3014,284,261shares91
2025-01-01 to 2025-06-3013,853,305shares181
2024-04-01 to 2024-06-308,167,993shares91
2024-01-01 to 2024-06-308,122,333shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.43USD/shares91
2025-01-01 to 2025-06-30-0.81USD/shares181
2024-04-01 to 2024-06-30-0.44USD/shares91
2024-01-01 to 2024-06-30-0.66USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.43USD/shares91
2025-01-01 to 2025-06-30-0.81USD/shares181
2024-04-01 to 2024-06-30-0.44USD/shares91
2024-01-01 to 2024-06-30-0.66USD/shares182

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-06-30229,725USD181
2024-01-01 to 2024-06-30621,395USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-6,016,088USD91
2025-01-01 to 2025-06-30-11,142,362USD181
2024-04-01 to 2024-06-30-3,553,834USD91
2024-01-01 to 2024-06-30-5,261,192USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-3010,996,731USD
At 2024-12-315,378,307USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-308,544,165USD
At 2024-12-312,306,229USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-06-301,770,178USD
At 2024-12-311,284,612USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-04-01 to 2025-06-306,016,088USD91
2025-01-01 to 2025-06-3011,142,362USD181
2024-04-01 to 2024-06-303,553,834USD91
2024-01-01 to 2024-06-305,261,192USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-04-01 to 2025-06-301,439,564USD91
2025-01-01 to 2025-06-303,445,778USD181
2024-04-01 to 2024-06-301,277,158USD91
2024-01-01 to 2024-06-301,598,535USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-3015,936,266shares
At 2024-12-3111,816,721shares
At 2024-10-2810,846,721shares
At 2024-10-2721,693,560shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-06-309,669,546USD
At 2024-12-314,164,323USD
At 2024-06-308,408,199USD
At 2023-12-311,719,338USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-06-305,597,106USD
At 2024-12-311,520,412USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2025-06-303,248,710USD
At 2025-03-312,147,554USD
At 2024-12-313,134,704USD
At 2024-06-307,073,588USD
At 2024-03-31-559,957USD
At 2023-12-311,111,448USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-06-30220,999USD
At 2024-12-31268,571USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-06-30266,155USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-6,176,084USD91
2025-01-01 to 2025-06-30-11,278,492USD181
2025-01-01 to 2025-03-31-5,102,408USD90
2024-04-01 to 2024-06-30-3,632,859USD91
2024-01-01 to 2024-06-30-5,340,217USD182
2024-01-01 to 2024-03-31-1,707,358USD91

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-6,176,084USD91
2025-01-01 to 2025-06-30-11,278,492USD181
2024-04-01 to 2024-06-30-3,632,859USD91
2024-01-01 to 2024-06-30-5,340,217USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-304,576,524USD91
2025-01-01 to 2025-06-307,696,584USD181
2024-04-01 to 2024-06-302,276,676USD91
2024-01-01 to 2024-06-303,662,657USD182

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-159,996USD91
2025-01-01 to 2025-06-30-136,130USD181
2024-04-01 to 2024-06-30-79,025USD91
2024-01-01 to 2024-06-30-79,025USD182

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2025-01-01 to 2025-06-3070,080USD181
2024-01-01 to 2024-06-300USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-06-30404,670USD181
2024-01-01 to 2024-06-30655,242USD182

Inspect the source

Entity
MEDICUS PHARMA LTD. / CIK 0001997296
Captured
2026-09-21T17:38:08.934Z
SEC response SHA-256
b65a7a242837977da8593ce20d7eec351b321004a1d0fddaa4991c5712b3c3ee

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001997296.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))